Ovarian Cancer

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.

INX-315, a CDK2 inhibitor, received FDA fast track designation for patients with CCNE1-amplified platinum-resistant ovarian cancer.

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched.

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.

Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial.

Having a life-threatening disease reminds me daily to make the most of whatever time I have.

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

Every treatment bag should include an unlimited supply of humor. Stuff will happen. It’ll be hard, but you may learn to laugh about it later, like I did.

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

Nearly 12 years after being diagnosed with ovarian cancer, Julie Brokaw believes life is a miracle.

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.

In the cancer world — or anywhere — the ability to give thanks in the midst of trials is an acquired skill. It must be practiced.

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

The FDA received the New Drug Application for avutometinib plus defactinib as a potential treatment option for previously treated low-grade serous ovarian cancer.

Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.

Results from the RAMP 201 clinical trial are promising for patients with recurrent low-grade serous ovarian cancer.

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.

From Ann Wilson’s return to Heart after chemotherapy to Ryan Reynolds visiting a fan with cancer, here’s what’s happening in the oncology space this week.

A Lynparza/cediranib combo had similar results versus standalone Lynparza among patients with relapsed platinum-sensitive ovarian cancer.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing my mind, body and soul.

Even though my wife became quadriplegic after her breast cancer progressed, our insurance still did not help us out, so I became her caregiver full-time.

My health care team was monitoring me for cancer due to a BRCA mutation. When a hysterectomy got delayed for various reasons, I ended up with ovarian cancer.

Here are eight poems about my experience as a caregiver to my wife during her final days.

My wife faced ovarian cancer, breast cancer and multifocal motor neuropathy, and I was her only caregiver.

After leaving an unsupportive support group for ovarian cancer, I finally found my pillars of support.

Having my omentum removed after an ovarian cancer diagnosis impacted my quality of life.